Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takayuki Furuishi has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Crystal Structure and Enhanced Physicochemical Properties of a Famotidine−Saccharin Salt

    by Takahiro Ichikawa, Motoki Inoue, Ryuma Koketsu, Takefumi Yamashita, Takayuki Furuishi, Etsuo Yonemochi

    A hydrated salt crystal comprising famotidine (FMT) and saccharin (SAC) was synthesized via liquid-assisted grinding and solvent evaporation. Single-crystal X-ray diffraction results revealed that the FMT−SAC salt crystallized in the triclinic space group P-1, comprising an FMT cation, SAC anion, and water molecule in each asymmetric unit. The structure features a distinct layered packing motif, stabilized by a hydrogen bonding network with R22(8), R22(10), and R44(34) motifs, while water molecules function as bridges. FMT−SAC exhibited significantly improved physicochemical properties with 5- and 9-fold higher aqueous solubility and intrinsic dissolution rates, respectively, than pure FMT. Tableting performance of FMT−SAC was remarkably enhanced. Moreover, the FMT−SAC tablet prevented capping under strong compaction forces. These improvements were attributed to the exposure of a hydrophilic surface of the salt with low attachment energy and a slip plane owing to the presence of lattice water molecules. This study establishes a structure−property relation, highlighting the utility of salt formation and hydrate engineering for enhancing the solubility and mechanical performance of poorly compressible drugs.

  • Open Access

    Ion-Containing Mesoporous Silica-Based Nanomaterials for Bone Regeneration: Emphasis on In Situ Co-Condensation, Multifunctional Bioactivity, and Spatiotemporal Delivery

    by Nutchalin Isariyavuth, Chomploy Renumas, Jarupha Meeyim, Yoshinori Onuki, Takefumi Yamashita, Motoki Inoue, Takayuki Furuishi, Pakorn Kraisit

    Bone defects remain difficult to treat because conventional grafting approaches may cause infection, inflammation, donor-site morbidity, or graft rejection. Mesoporous silica nanoparticles (MSNs) have emerged as versatile nanomaterials for drug delivery owing to their large surface area, tunable pore structure, high loading capacity, and readily modifiable surfaces. However, conventional MSNs are relatively bioinert and provide limited direct stimulation of bone regeneration. Incorporating therapeutic metal ions into the silica framework through in situ co-condensation can improve their biological activity while retaining their drug-delivery advantages. This review highlights recent advances in ion-doped MSNs as multifunctional delivery systems for bone regeneration, focusing on their osteogenic, angiogenic, anti-inflammatory, and antibacterial effects. The review discusses how ion doping influences particle structure, biodegradation, drug loading, and release behavior and the potential of single- and multiple-ion systems to provide complementary or, where experimentally demonstrated, synergistic therapeutic effects. Particular attention is given to controlled and spatiotemporal delivery strategies designed to match the sequential phases of bone healing. Future research should improve synthetic reproducibility, establish ion-specific therapeutic windows, integrate stimuli-responsive release mechanisms, and confirm long-term safety and efficacy in clinically relevant animal models.

  • Open Access

    Elucidating the Role of TPGS in Felodipine/PVPVA Amorphous Solid Dispersions during Water Uptake: Dissipative Particle Dynamics Simulations using Quantum Chemistry-based Interaction Parameters

    by Chinatsu Kobayashi, Naoko Konami, Yumika Ogura, Koji Okuwaki, Kenjirou Higashi, Motoki Inoue, Takefumi Yamashita, Takayuki Furuishi, Kaori Fukuzawa, Etsuo Yonemochi

    Amorphous solid dispersions (ASDs) are an effective formulation approach for improving the solubility of poorly water-soluble drugs. Nevertheless, their drug-release performance depends on the phase separation morphology during the dissolution process. Although the addition of surfactants has been experimentally reported to improve the dissolution behavior of ASDs, experimental methods alone are insufficient to resolve the complex and heterogeneous intermolecular interactions between drugs and excipients in multicomponent systems at the molecular level. In this study, we used dissipative particle dynamics simulations, which efficiently analyze mesoscopic phenomena such as phase separation, to explore the mechanisms of phase separation, water uptake, and drug release. Interaction parameters (𝜒) were derived from quantum chemical calculations and used to parameterize the coarse-grained model. We compared binary ASDs composed of felodipine and poly(vinylpyrrolidone-co-vinyl acetate) with ternary ASDs that additionally contained the surfactant d-α-tocopherol polyethylene glycol 1000 succinate (TPGS), focusing on the functional role of the surfactant. Results showed that drug release from ASDs is strongly governed by the competition between the rates of water uptake and drug aggregation, with interfacial liquid-liquid phase separation acting as a ratemodulating factor. In particular, in the ternary system containing TPGS, drug aggregation is mitigated through accelerated hydration, suppression of interfacial energy growth, and steric stabilization by TPGS molecules, enabling more efficient drug diffusion into the aqueous phase. These behaviors are consistent with previous experimental observations. Overall, this study provides a mechanistic, simulation-based framework for understanding phase separation and drug release processes in ASDs, thereby guiding formulation design, particularly for surfactantcontaining systems.

  • Elucidating the role of TPGS in felodipine/PVPVA amorphous solid dispersions during water uptake: dissipative particle dynamics simulations using quantum chemistry-based interaction parameters

    by Chinatsu Kobayashi, Naoko Konami, Yumika Ogura, Koji Okuwaki, Kenjirou Higashi, Motoki Inoue, Takefumi Yamashita, Takayuki Furuishi, Kaori Fukuzawa, Etsuo Yonemochi


  • Open Access

    Biocompatible Choline- and Amino Acid-Based Ionic Liquids: Applications in Pharmaceutical Science

    by Takayuki Furuishi

    In pharmaceutical development, synthesizing active pharmaceutical ingredients (APIs) for small-molecule and macromolecular compounds has become increasingly challenging. Many APIs under development do not have optimal solubility, membrane permeability, or stability, substantially complicating formulation or rendering it impossible. Ionic liquids (ILs) have attracted attention in the pharmaceutical field because their chemical structures can be tailored. Moreover, ILs have simple preparation processes and afford high solubility and chemical and thermal stability. However, the use of conventional ILs in pharmaceutical development is limited owing to concerns about biocompatibility, toxicity, and environmental impact. Therefore, in response to these challenges, greater focus has been placed on developing biocompatible ILs, in which both the cation and anion are composed of components that are biologically compatible and/or capable of reducing the environmental burden. This review focuses on ILs developed from biologically related components, especially biocompatible ILs derived from choline and amino acids. Furthermore, it discusses their use in pharmaceuticals, such as catalysts for API synthesis, crystallization, improving solubility, enhancement of skin permeation, designing oral formulations, antibacterial agents, and protectants for macromolecules. Additionally, this review explores how converting APIs into ILs with choline or amino acids can improve their physicochemical properties.

  • Open Access

    Enhancing the Physicochemical Properties of Trimethoprim through Complexation with Sulfathiazole

    by Motoki Inoue, Masataka Ito, Yohei Utsumi, Li Ye, Takefumi Yamashita, Takayuki Furuishi, Kaori Fukuzawa, Etsuo Yonemochi

    Small-molecule drug candidates often encounter challenges related to physicochemical properties, such as poor solubility and stability. Modifying the crystal form of these compounds is a promising approach to overcoming these challenges. Herein, trimethoprim (TMP), a biopharmaceutics classification system (BCS) class II drug with low water solubility, and sulfathiazole (STZ), a polymorphic sulfa drug, were selected as model active pharmaceutical ingredients. A TMP–STZ complex was prepared using liquid-assisted grinding, yielding anhydrous and ethanol-solvated forms. Physicochemical analyses confirmed that the complexes formed stable salt crystals, reducing hygroscopicity and improving thermal stability. An ethanol solvate demonstrated enhanced stability but exhibited a decreased melting point due to desolvation. Single-crystal structure analysis revealed strong hydrogen-bonding interactions between TMP and STZ, contributing to the stability of the crystal. Structural analysis confirmed proton transfer between TMP and STZ, forming a stable salt. Reduced hygroscopicity and improved thermal stability indicate enhanced solid-state robustness of TMP. These results provide a structural basis for controlling the solid-state stability of TMP by salt formation.


  • Open Access

    Dynamical Fragment Molecular Orbital Interaction Analysis of SARS-CoV-2 RNA-Dependent RNA Polymerase and Remdesivir

    by Shuhei Miyakawa, Koji Okuwaki, Yusuke Kawashima, Yuma Handa, Takayuki Furuishi, Etsuo Yonemochi, Koichiro Kato, Kaori Fukuzawa

    Remdesivir was developed as a nucleoside analogue inhibitor targeting the RNA-dependent RNA polymerase (RdRp) of the Ebola virus. It was shown to be an effective treatment for coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir is incorporated into the RdRp of SARS-CoV-2, and it becomes inactivated when remdesivir comes to the −3 position by adding three nucleotides behind. However, the detailed molecular mechanism of its inactivation remains unknown. In this study, we performed dynamic interaction analysis combining classical molecular dynamics (MD) simulations and fragment molecular orbital (FMO) calculations on the structures of RdRp and RNA complexes with remdesivir at four different positions. The results showed that the interaction between remdesivir at position −3 and Lys593 has significant importance in inhibiting RNA elongation of RdRp. Therefore, the combination of MD and FMO calculations is a useful method to clarify the molecular recognition mechanism in the biological environment.


  • Open Access

    Dynamical fragment molecular orbital interaction analysis of SARS-CoV-2 RNA-dependent RNA polymerase and remdesivir

    by Shuhei Miyakawa, Koji Okuwaki, Yusuke Kawashima, Yuma Handa, Takayuki Furuishi, Estuo Yonemochi, Koichiro Kato, Kaori Fukuzawa

    Remdesivir was developed as a nucleoside analog inhibitor targeting the RNA-dependent RNA polymerase (RdRp) of the Ebola virus. It was shown to be an effective treatment for coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir is incorporated into the RdRp of SARS-CoV-2, and it becomes inactivated when remdesivir comes to the −3 position by adding three nucleotides behind. However, the detailed molecular mechanism of its inactivation remains unknown. In this study, we performed a dynamical interaction analysis combining classical molecular dynamics (MD) simulations and fragment molecular orbital (FMO) calculations on the structures of RdRp and RNA complexes with remdesivir at four different positions. The results showed that the interaction between remdesivir at position −3 and Lys593 has significant importance in inhibiting RNA elongation of RdRp. Therefore, the combination of MD and FMO calculations a useful method to clarify the molecular recognition mechanism in the biological environment.

  • Open Access

    Film Coating of Small Molded Tablets for Pediatric Formulations with Rapid Disintegration and Bitterness-Masking Properties

    by Yuki Takahashi, Takayuki Furuishi, Etsuo Yonemochi

    The bitter taste of drugs is an important impediment to medication adherence for pediatric patients. To develop a formulation that can be easily taken by pediatric patients, we prepared film-coated molded tablets to mask their bitterness and investigated their properties. We manufactured 5 and 3 mm film-coated tablets, which were easy for children to swallow. The tablets also exhibited rapid disintegration (≤30 s), making them suitable for tube administration. The formulation of the film-coating layer was experimentally optimized. Tablets (measuring 5 and 3 mm thick) containing the model drug dextromethorphan hydrobromide were film-coated by weight of the uncoated tablets (4% by weight). These tablets rapidly disintegrated and masked the bitterness for 10 s. An examination of the coated tablets revealed that the film covered the periphery, which may mask the bitterness. The findings demonstrate that coating small molded tablets with a film enables the manufacture of tablets that could be more tolerable for pediatric patients and suitable for tube administration.